NCT06462404 - A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

March 17, 2025

Study Completion Date

March 17, 2025

Conditions

Narcolepsy Type 1 (NT1)

Interventions

DRUG

E2086

E2086 oral tablets.

DRUG

E2086 Placebo

E2086 matching placebo tablet.

DRUG

Active Comparator

Active comparator oral tablets.

DRUG

Active Comparator Placebo

Active comparator matching placebo tablet.

Trial Locations (14)

27410

Advances Repiratory and Sleep Medicine, Greensboro

27534

Medical Care Inc., Goldsboro

28037

Research Carolina Elite, Denver

29201

Bogan Sleep Consultants, LLC, Columbia

30281

Clinical Research Institute, Stockbridge

31210

Sleep Practioners, LLC, Macon

33126

PharmaDev Clinical Research, Miami

45245

Intrepid Research, LLC, Cincinnati

48911

SDS Clinical Trials, Santa Ana

Sound Asleep Research, Inc., Lansing

77478

Comprehensive Sleep Medicine Associates, Sugar Land

78229

Sleep Therapy and Research Center, San Antonio

L3R 1A3

AMDX Inc., Markham

M5S 3A3

Jodha Tishon Inc, Toronto

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY